Business
Admission of Shares to Official List
Admission of Shares to Official List.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \n \n 7 February 2023\n \n \n \n \n \n \n Hemogenyx Pharmaceuticals plc\n \n \n \n \n \n \n \n (\"Hemogenyx Pharmaceuticals\" or the \"Company\")\n \n \n \n \n \n \n Admission of Shares to Official List\n \n \n \n \n \n \n Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has applied to the Financial Conduct Authority to admit 2 ordinary shares of 1 pence each in the Company to the Official List in relation to a historical transaction. It is expected that the shares will be admitted on or around 8 February 2023. The total issued share capital of the Company will remain 1,141,999,321 ordinary shares of 1 pence each, none of which are held in treasury.\n \n \n \n \n \n \n Enquiries:\n \n \n \n \n \n \n \n \n \n \n \n \n \n Hemogenyx Pharmaceuticals plc\n \n \n \n \n \n \n \n https://hemogenyx.com\n \n \n \n \n \n \n \n \n Dr Vladislav Sandler, Chief Executive Officer & Co-Founder\n \n \n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n Peter Redmond, Director\n \n \n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n SP Angel Corporate Finance LLP\n \n \n \n \n \n Tel: +44 (0)20 3470 0470\n \n \n \n \n \n \n Matthew Johnson, Vadim Alexandre, Adam Cowl\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Peterhouse Capital Limited\n \n \n \n \n \n Tel: +44 (0)20 7469 0930\n \n \n \n \n \n \n Lucy Williams, Duncan Vasey, Charles Goodfellow\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n ","length":6717,"tagName":"div"}]